248 related articles for article (PubMed ID: 11268435)
1. Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
Bertelli G; Queirolo P; Vecchio S; Angiolini C; Bergaglio M; Del Mastro L; Signorini A; Valenzano M; Venturini M
Anticancer Res; 2000; 20(5C):3659-61. PubMed ID: 11268435
[TBL] [Abstract][Full Text] [Related]
2. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients.
Tomás E; Kauppila A; Blanco G; Apaja-Sarkkinen M; Laatikainen T
Gynecol Oncol; 1995 Nov; 59(2):261-6. PubMed ID: 7590484
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
4. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
[TBL] [Abstract][Full Text] [Related]
5. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.
Zhou WB; Ding Q; Chen L; Liu XA; Wang S
Breast Cancer Res Treat; 2011 Aug; 128(3):625-31. PubMed ID: 21553116
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
[TBL] [Abstract][Full Text] [Related]
7. Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer.
Kashiyama T; Oda K; Kawana K; Arimoto T; Kanetaka Y; Takazawa Y; Maeda D; Nakagawa S; Yano T; Kozuma S
J Obstet Gynaecol Res; 2013 Jan; 39(1):424-9. PubMed ID: 22690656
[TBL] [Abstract][Full Text] [Related]
8. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
Gu R; Jia W; Zeng Y; Rao N; Hu Y; Li S; Wu J; Jin L; Chen L; Long M; Chen K; Chen L; Xiao Q; Wu M; Song E; Su F
BMC Cancer; 2012 May; 12():161. PubMed ID: 22548922
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.
Kimura M; Tominaga T; Kimijima I; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Breast Cancer; 2014 May; 21(3):275-83. PubMed ID: 22968626
[TBL] [Abstract][Full Text] [Related]
10. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
; Pagani O; Gelber S; Price K; Zahrieh D; Gelber R; Simoncini E; Castiglione-Gertsch M; Coates AS; Goldhirsch A
Ann Oncol; 2004 Dec; 15(12):1749-59. PubMed ID: 15550579
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
[TBL] [Abstract][Full Text] [Related]
12. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
Kusama M; Kaise H; Nakayama S; Ota D; Misaka T; Aoki T
Breast Cancer Res Treat; 2004 Nov; 88(1):9-16. PubMed ID: 15538041
[TBL] [Abstract][Full Text] [Related]
13. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
[TBL] [Abstract][Full Text] [Related]
14. Phase III trials of toremifene vs tamoxifen.
Gams R
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):23-8. PubMed ID: 9165503
[TBL] [Abstract][Full Text] [Related]
15. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Mäenpää JU; Ala-Fossi SL
Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy.
Buzdar AU; Hortobagyi GN
J Clin Oncol; 1998 Jan; 16(1):348-53. PubMed ID: 9440763
[TBL] [Abstract][Full Text] [Related]
17. Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene.
Wallén M; Tomás E; Visakorpi T; Holli K; Mäenpää J
Cancer Chemother Pharmacol; 2005 Apr; 55(4):343-346. PubMed ID: 15592834
[TBL] [Abstract][Full Text] [Related]
18. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
[TBL] [Abstract][Full Text] [Related]
20. Evolving role of toremifene in the adjuvant setting.
Holli K
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):48-51. PubMed ID: 9165507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
